Steven Szabo is a Psychiatry physician affiliated with Sumitomo Dainippon Pharma. OpenAlex indexes 126 publications with 4,267 citations (h-index 33); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2213 Elba St.
Duke University Psychiatry Civitan Building, Rm 120
Durham, NC 27705
Telephone
919-684-2258Registry record last updated 8 Apr 2009.
Clinical trials
- Neurosteroids in PTSD - Biomarkers to Therapeutics
Sponsor: VA Office of Research and Development
- Effect of Bupropion on Seizure Threshold in Depressed Patients
Sponsor: Duke University
- A Pilot Dose-Response Biomarker Study of Brexpiprazole Treatment in PTSD
Sponsor: Duke University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Neurocrine BioSciences, Inc.Program year20251 payment
- GlaxoSmithKline, LLC.Program year20251 payment
- Neurocrine Biosciences, Inc.Program year20242 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
1 NIH research award on record, funded 2018–2021 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Xanomeline-trospium (Cobenfy<sup>TM</sup>) for Schizophrenia: A Review of the Literature
Clinical Psychopharmacology and Neuroscience
2024 - Enhancing cognitive restructuring with concurrent fMRI-guided neurostimulation for emotional dysregulation–A randomized controlled trial
Journal of Affective Disorders
2022 - Ketamine for Treatment of Mood Disorders and Suicidality: A Narrative Review of Recent Progress
Annals of Clinical Psychiatry
2021 - Enhancing Cognitive Restructuring with Concurrent Repetitive Transcranial Magnetic Stimulation: A Transdiagnostic Randomized Controlled Trial
Psychotherapy and Psychosomatics
2021
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”